{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:15:00Z","timestamp":1778681700287,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12185-026-04189-z","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:47:29Z","timestamp":1773053249000},"page":"629-638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current status and issues with CAR-T cell products in Japan: a regulatory perspective"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-7449","authenticated-orcid":false,"given":"Miki","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinich","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"4189_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"4189_CR2","first-page":"121","volume":"54","author":"A Nisikawa","year":"2023","unstructured":"Nisikawa A, Noda S, Okudaira S, Shinohara K, Nakamura M, Maruyama Y, et al. CAR-T cell therapy from a regulatory perspective. PMDRS. 2023;54:121\u20138.","journal-title":"PMDRS"},{"key":"4189_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-031-34567-8_9","volume":"1430","author":"Y Maruyama","year":"2023","unstructured":"Maruyama Y, Noda S, Okudaira S, Sakurai A, Okura N, Honda F. Regulatory aspects of cell and gene therapy products the Japanese perspective. Adv Exp Med Biol. 2023;1430:155\u201379.","journal-title":"Adv Exp Med Biol"},{"key":"4189_CR4","unstructured":"Pharmaceuticals and Medical Devices Agency. Kymriah suspension for intravenous infusion review reports. Tokyo: Pharmaceutical and Medical Devices Agency. 2019, 2022."},{"key":"4189_CR5","unstructured":"Pharmaceuticals and Medical Devices Agency. YESCARTA Intravenous drip infusion review report. Tokyo: Pharmaceuticals and Medical Devices Agency. 2020, 2022."},{"key":"4189_CR6","unstructured":"Pharmaceuticals and Medical Devices Agency. Breyanzi suspension for intravenous infusion review report. Tokyo: Pharmaceuticals and Medical Devices Agency. 2021, 2022, 2024."},{"key":"4189_CR7","unstructured":"Pharmaceuticals and Medical Devices Agency. Abecma intravenous infusion review report. Tokyo: Pharmaceuticals and Medical Devices Agency. 2021."},{"key":"4189_CR8","unstructured":"Pharmaceuticals and Medical Devices Agency. Carvykti suspension for intravenous infusion review report. Tokyo: Pharmaceuticals and Medical Devices Agency. 2022."},{"key":"4189_CR9","unstructured":"Pharmaceutical Safety and Environmental Health Bureau, Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Japan, Guidelines on Cancer Immunotherapy Development, PSEHB\/PED Notification No. 0308-1, PSEHB\/MDED Notification No. 0308-1, 2019"},{"key":"4189_CR10","unstructured":"Food and Drug Administration, the USA, Considerations for the development of chimeric antigen receptor (CAR) T cell products\/guidance for industry; Food and Drug Administration 2024."},{"key":"4189_CR11","unstructured":"European Medicines Agency, the EU, Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells European Medicines Agency. 2021."},{"key":"4189_CR12","unstructured":"Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Japan, Guidelines for clinical evaluation methods of anticancer drugs. PSEHB\/PED Notification No. 0331-1, 2021."},{"key":"4189_CR13","unstructured":"Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Japan, Basic principles on Global Clinical Trials. PFSB\/ELD. Notification No. 0928010, 2007."},{"key":"4189_CR14","unstructured":"Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Japan, Handling of conditional and time-limited approval scheme for regenerative medical products PSEHB\/MDED Notification No. 1006-1, 2025"},{"key":"4189_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4189_CR16","unstructured":"National Comprehensive Cancer Network, Management of CAR T\u2014cell and lymphocyte engager-related toxicites, version 1. 2026, 2025"},{"issue":"2","key":"4189_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32.","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"4189_CR18","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison SJ, Nguyen T, Rahman M, Er J, Li J, Li K, et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood. 2023;142(Supplement 1):6939\u201340.","journal-title":"Blood"},{"key":"4189_CR19","unstructured":"Pharmaceuticals and Medical Devices Agency, Ministry of Health, Labour and Welfare, Japan. Technical guidance for quality, and nonclinical and clinical studies of regenerative medicines (human cell-processed therapeutic products). PSEHB\/MDED administrative notice. Tokyo: Ministry of Health, Labour and Welfare. 2016."},{"key":"4189_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04343-0","volume":"16","author":"M Sasai","year":"2025","unstructured":"Sasai M, Kitawaki Y, Umezawa A, Oie Y, Kamiya T, Kawamura T, et al. Challenges and opportunities in the compassionate use of out\u2011of\u2011specification products in autologous regenerative medicine. Stem Cell Res Ther. 2025;16:238.","journal-title":"Stem Cell Res Ther"},{"key":"4189_CR21","first-page":"114","volume":"54","author":"Y Tsurumaki","year":"2023","unstructured":"Tsurumaki Y. Cellular gene therapy: current status and challenges of commercialization of chimeric antigen receptor (CAR) T cell therapy in Japan. PMDRS. 2023;54:114\u201320.","journal-title":"PMDRS"},{"key":"4189_CR22","unstructured":"Food and Drug Administration, Expanded Access Program Report. 2018. https:\/\/www.fda.gov\/media\/119971\/download"},{"key":"4189_CR23","unstructured":"European Commission. Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products. 2017. https:\/\/health.ec.europa.eu\/document\/download\/ad33d9dd-03f0-4bef-af53-21308ce2187d_en?filename=2017_11_22_guidelines_gmp_for_atmps.pdf"},{"key":"4189_CR24","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood.2021012392","volume":"138","author":"J Rossoff","year":"2021","unstructured":"Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, et al. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021;138:2138\u201342.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4189_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136136","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Locke F, Miklos DB, Vose JM, Lin Y, Budde LE, et al. Outcomes of patients (Pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (Axi-Cel) in relapsed\/refractory large B cell lymphoma (R\/R LBCL) for expanded access and commercial out-of-specification (OOS) product. Blood. 2020;136(Supplement 1):2.","journal-title":"Blood"},{"key":"4189_CR26","first-page":"45","volume":"380","author":"A Santoro","year":"2023","unstructured":"Santoro A, Philippis C, Zucchinetti C, Mannina D, Krampera M, Zinzani PL, et al. Retrospective multicentric comparison of out-of-specification and standard-of-care tisagenlecleucel infusion for diffuse large B-cell lymphoma. Res Square. 2023;380:45.","journal-title":"Res Square"},{"key":"4189_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01225-9","volume":"15","author":"V Dulobdas","year":"2025","unstructured":"Dulobdas V, Kirkwood A, Serpenti F, Gautama B, Panopoulou A, Mathew A, et al. Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel. Blood Cancer J. 2025;15:30.","journal-title":"Blood Cancer J"},{"key":"4189_CR28","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jcyt.2025.04.067","volume":"27","author":"K Kato","year":"2025","unstructured":"Kato K, Kato J, Goto H, Kobayashi T, Takahashi Y, Sakaida E, et al. Clinical outcomes of Japanese patients treated with out-of-specification Tisagenlecleucelina a phase 3b trial. Cytotherapy. 2025;27:938\u201343.","journal-title":"Cytotherapy"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04189-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:30:08Z","timestamp":1778679008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04189-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4189"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04189-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}